Zai Ding Pharmaceuticals (09688.HK) reported a total revenue of 99.6 million US dollars in the first quarter.

Wisdom Financial News APP, China Resources Medical Health (09688.HK) announced that in the first quarter of 2026, total revenue was 99.6 million US dollars, compared to 106.5 million US dollars in the same period in 2025, a year-on-year decrease of 6%. The net product revenue in the first quarter of 2026 was 95.6 million US dollars, compared to 105.7 million US dollars in the same period in 2025, a year-on-year decrease of 10%, and a 12% decrease when calculated at a fixed exchange rate (CER). The net loss in the first quarter of 2026 was 51 million US dollars, with a basic loss per share of 0.05 US dollars attributable to common shareholders.